Anti-Human PCSK9 Recombinant Antibody(Bococizumab)
-
产品编号
YR1327
-
别名
科研级 Bococizumab ( 伯考赛珠单抗 ), Anti-PCSK9 Recombinant Antibody, Research Grade Bococizumab
-
规格
- 1mg
- 5mg
产品介绍
| Alias | 科研级 Bococizumab ( 伯考赛珠单抗 ), Anti-PCSK9 Recombinant Antibody, Research Grade Bococizumab |
| Catalog Number | YR1327 |
| Molecular Name | Bococizumab |
| Size | 1mg, 5mg |
| Clonity | Monoclonal |
| Purity | >95% as determined by SDS-PAGE |
| Concentration | 1mg/ml |
| Antibody Isotype | IgG2 Kappa |
| Formulation | PBS, pH7.5 |
| Background | Bococizumab (USAN, development code RN316) is a drug that was in development by Pfizer targeting PCSK9 to reduce LDL cholesterol. Pfizer withdrew the drug from development in November 2016, determining that it was "not likely to provide value to patients, physicians or shareholders." |
| CAS Number | 1407495-02-6 |
| Application | FCM, IP, ELISA, Neut, FuncS |
| Storage Condition | It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles. |
| Remarks | This product is for research use only. |
| Shipping Condition | Shipped on ice packs. |
| Target | PCSK9[Homo sapiens] |
- 联系我们
- 电话：400-621-6806
- 手机：13116038708
- 邮箱：info@kmdbioscience.com
- 地址：天津市武清区国际企业社区A5号楼
-
销售微信
-
官方公众号
-
400-621-6806 -
614353794 -
周一至周五 9:00-18:00 -
-
0
-
